GCP
CSTL icon

GSA Capital Partners’s Castle Biosciences CSTL Stock Holding History

GSA Capital Partners’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,236
Closed -$300K – 1810
2026
Q1 		$300K Buy
+12,236
New +$401K 0.02% 1250
2025
Q2 		– Sell
-67,143
Closed -$1.34M – 1801
2025
Q1 		$1.34M Sell
67,143
-3,658
-5% -$90.6K 0.12% 210
2024
Q4 		$1.89M Buy
70,801
+18,974
+37% +$578K 0.14% 97
2024
Q3 		$1.48M Buy
+51,827
New +$1.32M 0.11% 226
2024
Q2 		– Sell
-52,448
Closed -$1.16M – 1687
2024
Q1 		$1.16M Buy
52,448
+4,352
+9% +$94.7K 0.09% 349
2023
Q4 		$1.04M Sell
48,096
-4,099
-8% -$72.1K 0.09% 372
2023
Q3 		$882K Buy
52,195
+11,280
+28% +$197K 0.08% 470
2023
Q2 		$561K Buy
40,915
+8,626
+27% +$175K 0.06% 671
2023
Q1 		$734K Buy
32,289
+5,393
+20% +$132K 0.07% 485
2022
Q4 		$633K Sell
26,896
-38,353
-59% -$889K 0.08% 452
2022
Q3 		$1.7M Buy
+65,249
New +$1.83M 0.23% 34

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GSA Capital Partners's CSTL Position: Q2 2026 in Review

GSA Capital Partners sold out of Castle Biosciences (CSTL) in Q2 2026, closing a stake of 12,236 shares — an estimated $300K sold.

GSA Capital Partners first reported a position in CSTL in Q3 2022 and held it in 11 quarters. The position peaked at $1.89M in Q4 2024. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • GSA Capital Partners reported no remaining Castle Biosciences position as of Q2 2026 after selling out during the quarter.
  • GSA Capital Partners sold 12,236 Castle Biosciences shares in Q2 2026, an estimated $300K.
  • GSA Capital Partners first reported a position in Castle Biosciences in Q3 2022 and held it in 11 quarters.
  • GSA Capital Partners's Castle Biosciences position peaked at $1.89M in Q4 2024.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.